For: | Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol 2020; 26(38): 5896-5910 [PMID: 33132643 DOI: 10.3748/wjg.v26.i38.5896] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v26/i38/5896.htm |
Number | Citing Articles |
1 |
KASL clinical practice guidelines for management of autoimmune hepatitis 2022. Clinical and Molecular Hepatology 2023; 29(3): 542 doi: 10.3350/cmh.2023.0087
|
2 |
Linda Skibsted Kornerup, Lisbet Grønbæk, Mikkel Breinholt Kjær, Henning Grønbæk. Comprehensive Guide to Hepatitis Advances. 2023; : 429 doi: 10.1016/B978-0-323-98368-6.00026-4
|
3 |
Yang Zhang, Dehe Zhang, Ling Chen, Jing Zhou, Binbin Ren, Haijun Chen. The progress of autoimmune hepatitis research and future challenges. Open Medicine 2023; 18(1) doi: 10.1515/med-2023-0823
|
4 |
Ja Kyung Kim. Treatment of Autoimmune Hepatitis. The Korean Journal of Gastroenterology 2023; 81(2): 72 doi: 10.4166/kjg.2023.011
|